Showing results (261-270 of 343) with videos related to

Sort By:
Pageof 35
Wiener Klinische Wochenschrift|December 3, 2016
Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015Lukas Lunger, Andreas Melmer, Willi Oberaigner, et al.
Journal of Translational Medicine|December 6, 2019
Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational studyBenedetta M Motta, Christoph Grander, Martin Gögele, et al.
Gastroenterology|November 26, 2025
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal InflammationAlmina Jukic, Richard Hilbe, Luis Zundel, et al.
Transplantation|November 20, 2020
Live Confocal Imaging as a Novel Tool to Assess Liver Quality: Insights From a Murine ModelBenno Cardini, Margot Fodor, Martin Hermann, et al.
Diabetologia|December 16, 2022
Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosisBernhard Radlinger, Claudia Ress, Sabrina Folie, et al.
Journal of Hepatology|December 20, 2015
Lipocalin 2 drives neutrophilic inflammation in alcoholic liver diseaseVerena Wieser, Piotr Tymoszuk, Timon Erik Adolph, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 2, 2024
The BAR Score Predicts and Stratifies Outcomes Following Liver Retransplantation: Insights From a Retrospective Cohort StudyFelix J Krendl, Margot Fodor, Madita L Buch, et al.
Ebiomedicine|August 14, 2021
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19Andreas Zollner, Christina Watschinger, Annika Rössler, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 20, 2015
Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapyArmin Finkenstedt, Anja Vikoler, Manuela Portenkirchner, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
Pageof 35